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Abstract
Yellow fever is a viral hemorrhagic fever transmitted by the Aedes aegypti mosquito. It
has historically caused thousands of deaths throughout Africa, the Americas, Europe, and
the Caribbean and continues to pose threats in Africa and Central and South America.
The disease is most detrimental in densely populated areas with warmer climates where
individuals have limited access to health care facilities. These conditions are exemplified by
the yellow fever epidemic of 1878 in Memphis, Tennessee. The limited medical knowledge,
warm climate, and densely populated urban areas greatly contributed to the magnitude of the
epidemic that killed thousands. We have developed an ordinary differential equations model
to simulate the dynamics of human and mosquito populations during a yellow fever outbreak
using historical data. Additionally, we examined the use of insect repellent and vaccination
as methods to reduce the severity of the outbreak. We examined the conditions under which
the disease-free equilibria are stable for the complete model. We also used uncertainty and
sensitivity analyses to quantify the reduction in cumulative infections and deaths due to the
use of insect repellent and vaccination among humans.
Keywords: yellow fever, ordinary differential equations model, Memphis, vector-borne disease



1

Introduction

Yellow fever is a viral hemorrhagic fever transmitted by
the Aedes aegypti mosquito. It is estimated this disease evolved in Africa and spread to the western hemisphere through transcontinental slave trade [5, 8]. In humans, yellow fever has an incubation period that lasts
3–6 days, during which humans are asymptomatic and
non-infectious. Once the incubation period is complete,
the virus enters the blood stream, causing fever, myalgia,
nausea, and vomiting [2]. Shortly after becoming symptomatic, some see an improvement in symptoms mimicking recovery, but the disease may then worsen, causing
jaundice, internal bleeding, and death in some individuals [2].
During the early 1800s, when the field of medicine
was still in its infancy and the link between yellow fever
and mosquitoes had not yet been discovered, the United
States had several devastating yellow fever outbreaks that
resulted in the deaths of thousands. Memphis, Tennessee
had its first yellow fever outbreak in 1828, which spread
upstream from New Orleans [7, 11]. In 1878, Memphis
had its worst outbreak, totaling 17,000 cases and approximately 5,000 deaths [7, 11]; the daily death toll due to
yellow fever during the outbreak is shown in Figure 1.
While yellow fever is no longer a major concern in the
1 Department

of Mathematics, Rhodes College, Memphis, TN

www.sporajournal.org

United States, there has recently been a resurgence of the
disease throughout tropical regions of Africa, as well as
Central and South America [2]. There is no known cure
for yellow fever, and individuals visiting high risk areas
are encouraged to take precautionary measures to avoid
contracting the disease, such as vaccination [6]. The first
vaccine was developed in 1938, well after the deadliest
Memphis outbreak, by using an isolated viral strain from
a yellow fever survivor [17]. The attenuated vaccine is
very successful in preventing the spread of yellow fever
because it provides susceptible individuals effective, lifelong immunity from the yellow fever virus [17]. However,
immunity is only achieved after an incubation period during which individuals are still at risk of contracting the
disease, though at a lower rate than unvaccinated individuals [1].
Some limitations exist for vaccination in individuals
without access to reliable health care, individuals whose
beliefs do not support vaccinations, immunodeficient individuals, small children, and women who are pregnant.
Other control methods exist to prevent the outbreak
of yellow fever, including the use of insect repellent to
decrease the number of mosquito-to-human interactions
that spread yellow fever. Insect repellent is readily available and may be used by many individuals who cannot
receive vaccinations. The Centers for Disease Control
and Prevention (CDC) specifically recommends consis2018 Volume 4(1) page 15
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tent use of N,N-Diethyl-meta-toluamide insect repellent
(DEET) to avoid vector-born illnesses like yellow fever
[6]. Memphis dwellers hoping to quell yellow fever in the
1878 outbreak did not use any form of insect repellent as
a control measure because it was not discovered until the
early 1900s that mosquitoes are the vector of yellow fever
transmission [7, 17].
To our knowledge, there have been no other publications that study the combined effects of insect repellent
and vaccination on yellow fever epidemics using mathematical modeling. However, Kiszewski and Darling used
a static probability model to study the effectiveness of
insect repellent as a control measure against malaria, another disease carried by the Aedes aegypti [12]. Their
findings indicate that a very high degree of repellent efficacy is necessary to suppress malaria infection rates more
than by using bed nets [12]. The Kiszewski & Darling
model assumes a constant proportion of the population
wearing insect repellent and a constant efficacy of the
repellent. We use a different approach, proposing a dynamical systems model which simulates the waning effects of insect repellent over time and human’s propensity
to reapply repellent. Other differential equation models
have also looked at insect bite prevention strategies, such
as insect repellent and bed nets, coupled with additional
control measures to reduce the intensity of vector-borne
outbreaks of Zika virus and malaria [9, 14]. Similarly, we
hope to quantify the individual use of both insect repellent and vaccination, as well as their combined use, as
control measures during a yellow fever outbreak.

Figure 1: Deaths in Memphis, TN during the 1878 epidemic due to yellow fever, represented by the red data
points [11]. The solid black line is generated by the model
in System (1) with initial condition SH (0) = 17,000,
IH (0) = 2, RH (0) = 5,000, SM (0) = 950,000, IM (0) =
100, and all other states initialized to zero. The human
and mosquito parameter values used are given in Table 1,
and all control parameters were set to zero.

www.sporajournal.org
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2

The Model

The SEIR model depicts the dynamics of an infectious
disease spreading within a population by modeling the
change in the number of susceptible (S), exposed (E), infectious (I), and recovered (R) individuals over time. The
SEIR model is used to simulate infectious diseases with
an incubation period. An individual in the exposed state
is infected but not yet contagious and is usually asymptomatic, while an individual in the infectious state is contagious and symptomatic. We adapt the SEIR model to
simulate the transmission dynamics of yellow fever between a human population and a mosquito population,
denoted by subscripts H and M , respectively. Only the
susceptible, exposed, and infectious states are used for
the mosquito population since mosquitoes remain infected
with yellow fever until their death.
We assume the human and mosquito populations are
well mixed, and that yellow fever is only transmitted between Aedes aegypti and humans, without accounting for
vertical transmission in mosquitoes or yellow fever being transmitted to non-human primates. Since the time
scale of a few months is marginal compared with the average human life span, we assume changes to the total
human population through birth or background deaths
are negligible and thus excluded from the model. Interactions between mosquitoes and humans are reduced by
the use of insect repellent. Thus, our model includes additional states for humans wearing repellent as a control
measure, denoted by subscript R. Since the use of insect
repellent decreases human to mosquito interactions, the
probability of transmission is lower between infectious humans and mosquitoes. We assume a waning effectiveness
of repellent and that humans reapply repellent at a rate
dependent on the severity of the epidemic.
Humans can also avoid infection by receiving a vaccination [6]. In our model, humans that have received a
vaccination are denoted by subscript V . Individuals who
have been vaccinated move to the SV class where they remain susceptible but have a lower probability of becoming
infected with yellow fever from interactions with infected
mosquitoes. Individuals in the SV class who apply repellent move to the SRV class, and have increased protection
from yellow fever than if they were in the SV class. However, we do not include vaccination of individuals wearing repellent since the period of repellent effectiveness is
short, so they are unlikely to be vaccinated during this
time. If an individual in the SV class becomes infected
with yellow fever, the disease progresses typically, following the same incubation period and progression rates as
unvaccinated classes. After approximately 10 days, an
individual who has been vaccinated becomes immune to
infection from yellow fever and moves to the RV class [6].
A flow diagram depicting the transition between states
2018 Volume 4(1) page 16
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is given in Figure 2. The model is given by the following
system of equations:
Humans without Repellent or Vaccine

0
SH
= −βH SH IM − γS A + ρs SH + σSR
− αωSH

(1.1)

0
EH
= βH SH IM − κH EH − γS A + ρs EH



+ σER + βV SV IM

(1.2)

0
IH
= κH EH − νH IH − γI A + ρI IH + σIR



0
RH

= (1 − δ)νH IH + (1 − δ)νH IR

Humans with repellent, but no vaccine

0
SR
= −qβH SR IM + γS A + ρs SH − σSR

0
ER
= qβH SR IM − κH ER + γS A + ρs EH
− σER + qβV SRV IM

(1.3)
(1.4)

(1.5)
(1.6)

0
IR
= κH ER − νH IR + γI A + ρI IH − σIR



(1.7)

Humans who have been vaccinated

SV0 = αωSH − βV SV IM − γV A + ρV SV
+ σSRV − χSV
0
SRV
RV0

(1.8)


= −qβV SRV IM + γV A + ρV SV − σSRV
= χSV

(1.9)
(1.10)

Mosquitoes
0
SM
= ΩM − βM SM IH − qβM SM IR − µM SM
0
EM
0
IM

(1.11)

= βM SM IH + qβM SM IR − (µM + κM )EM (1.12)
= κM EM − µM IM ,

(1.13)
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that asymptomatic individuals are more likely to increase
repellent use to avoid contracting yellow fever, while vaccinated and symptomatic individuals are less likely to
increase repellent use as the severity of an epidemic increases. Additionally, we assume the rate at which humans reapply repellent is dependent on the severity of
the outbreak at the time, thus the rate of reapplication is
the product of γ and the proportion of infectious individR
.
uals within the entire human population, i.e. A = IHN+I
H
Empirical data on the application rates of repellent
among humans is scarce. Thus, these parameters ranges
have been estimated using a wide range of reapplication
rates. The recommendation of the CDC to travelers visiting countries with mosquito-borne diseases is to reapply
repellent as protection wanes and mosquitoes start to bite
[6]. The rate of repellent waning, σ, was estimated using packaging information for repellent containing 40%
DEET repellent, which guarantees over eight hours of
protection. Allowing for four hours of increased or decreased longevity, we assume the repellent lasts between
4 and 12 hours. For each of the baseline application parameters, ρ, we assume that the maximum number of
applications is six per day when epidemic severity is not
taken into consideration and that every person is applying repellent at least once every seven days. We assume
that susceptible and exposed (asymptomatic) individuals
have the highest rate of repellent reapplication, followed
by vaccinated and then infectious individuals. The values of γ were calculated based on assumptions of repellent
application when 80% of the population is symptomatic,
and the baseline is assumed to be its highest value in these
calculations. Therefore,
γ=

time between application − baseline
.
0.8

We assume that asymptomatic, unvaccinated individR
, and NH is the size of the total hu- uals (S & E) are the most likely to apply repellent, so
where A = IHN+I
H
man population. The definitions, values, and units of all these individuals will apply between one and six times a
parameters can be found in Table 1.
day as a baseline, an average of 3.5 times daily, and increase application to twice a day on average when 80%
Application of Repellent · We include three param- of the population is symptomatic. We also assume that
eters (σ, ρ, and γ) to simulate the movement of indi- symptomatic individuals (I) are the least likely to apply
viduals between states with and without repellent. The repellent due to epidemic severity since they are not conparameter σ denotes the rate at which repellent becomes cerned about becoming infected, applying between once
ineffective due to wearing off over time. The parame- per day and once every seven days, and they will increase
ter ρ represents the baseline rate of repellent application application to every three days on average when the epiwhen humans are not considering the severity of the epi- demic worsens. Lastly, we assume that vaccinated indidemic when choosing to apply repellent. The parameter γ viduals (V ) are less likely to apply than unvaccinated, so
denotes the rate of reapplication above the baseline due they apply repellent between four times per day and once
to the presence of infectious humans. The parameters per week and will increase application to every 3 days on
ρ and γ are different for asymptomatic individuals, un- average. Each ρ and γ parameter was assigned a unique
vaccinated and symptomatic individuals, and vaccinated range of values (shown in Table 1) wherein the paramindividuals, denoted by parameter subscripts S, I, and eter value varies in uncertainty and sensitivity analyses
V , respectively. The variation is due to the assumption (see Section 3).
www.sporajournal.org
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Table 1: Model parameter units, values, and definitions.
Value

Ref

Definition

−7

3.69 · 10
4.3
3.875
0.303

§3
[10]
[1]
[11]

Transmission rate in humans
Intrinsic incubation period
Recovery time of humans
Proportion of infected individuals who die

§3
[20]
[20]
[10]

Transmission rate in mosquitoes
Lifespan of mosquitoes
Birth rate of mosquitoes
Extrinsic incubation period

βH
1/κH
1/νH
δ

1/(mosq · days)
days
days
—

βM
1/µM
ΩM
1/κM

1/(ppl · days)
days
mosq/day
days

9.69 · 10−5
33.3
28,500
10

βV
q
α
ω
χ
1/σ

1/(mosq · days)
—
1/days
—
1/days
days

βH /2
0.4
0.01–0.05
0.99
0.9/10
0.083–0.25

1/ρS
1/ρI
1/ρV
1/γS
1/γI
1/γV

days
days
days
days
days
days

0.16–2
1–7
0.167–7
0–0.625
0–8.750
0–5.000

Parameters for control measures

Humans

Units

Mosquitoes

Parameter

Transmission rate during vaccine incubation period
Effectiveness of insect repellent
Vaccination rate
Vaccine efficacy
Incubation rate for yellow fever vaccine in humans
Period of repellent effectiveness

[18]
[13]
[6]
[19]

Time between . . .
Base repellent application for susceptible/exposed humans
Base repellent application for infectious humans
Base repellent application for vaccinated humans
Repellent application for susceptible/exposed humans above baseline
Repellent application for infected humans above baseline
Repellent application for vaccinated humans above baseline

χ
γV A + ρV

SV

SRV

χ

RV

IH

(1 − δ)νH

σ
αω

βV

SH
σ

q βV

γS A + ρS

κH

EH

βH
σ

σ

γS A + ρS

γI A + ρI

SR

q βH

ER

κH

IR

IM

κM

EM

βM

SM

µM

µM

RH

(1 − δ)νH

Ω

µM

R
and NH denotes the total human
Figure 2: Flow diagram of the model given by System (1), where A = IHN+I
H
population. Gray and red boxes represent human and mosquito states, respectively. Solid arrows represent movement
of individuals between states, while dashed arrows represent interactions between individuals.
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Vaccination · The control parameters for vaccination
are based on empirical data. Values for the efficiency
and efficacy of yellow fever vaccination inherently have a
range of reasonable possibilities depending on host characteristics, vaccine characteristics, and differential access
to healthcare. From person to person, vaccine efficacy, ω,
can depend on the age of the host, comorbidity, and the
host’s prior exposure to the disease [16]. Efficacy can
also be influenced by the method of delivery and storage
of the vaccine prior to its injection in the host [16]. For
example, the yellow fever vaccine is most effective when
stored and transported at temperatures between 2◦ C and
8◦ C, and when the reconstituted vaccine is used within
one hour [13]. However, in most cases, the efficacy rate is
shown to be very high, so we assume a constant vaccine
efficacy of 0.99 [13].
Variation in vaccination rate, α, depends on a multitude of factors including the accessibility of healthcare in
the community, the availability of the vaccine, and proportion of the population that can reasonably be vaccinated daily due to these constraints. Thus, we explore
various vaccination rates in model simulations. We also
simulate the use of vaccination campaigns, where varying
proportions of the population are vaccinated prior to the
onset of the epidemic.
The yellow fever vaccine has a short incubation period
before it can provide effective immunity as the antibodies
build up within the immune system [1]. The production
of antibodies is a continuous process, where zero antibodies exist in the system prior to vaccination, and immunity
occurs after a certain threshold of antibodies have been
produced to allow the body to fight off infection. Therefore, we estimate the value of the transmission rate for
vaccinated individuals during the vaccine incubation period, βV , to be half of the transmission rate of unvaccinated individuals; thus, βV = βH /2.

Middleton, Deery, Bodine

pends on the rate of repellent application via parameters
σ and ρ. The disease-free equilibrium of the model with
vaccination (α 6= 0) is given by
EH ∗ = ER ∗ = IH ∗ = IR ∗ = SV ∗ = SRV ∗ = 0
EM ∗ = IM ∗ = 0
SH ∗ = SR ∗ = 0
ΩM
SM ∗ =
µM
RV ∗ = NH .

(3)

For the disease-free equilibrium with vaccination, the entire human population is in the fully vaccinated class
(RV ).

3

Methods

Using Historical Data to Estimate Transmission
Parameters · Historical data of the daily count from
the 1878 epidemic in Memphis, TN were used to estimate
model transmission rates, βH and βM . The total number
of deaths due to yellow fever each day from 21 July to
10 December was calculated using data from J. Keating’s
A History of the Yellow Fever and are shown as the red
data points in Figure 1 [11]. Using the parameter fitting
method described in [4], Latin hypercube sampling (LHS)
was used to create sets of parameters (βM , βH ) over a
wide range of potential transmission rate values. LHS is
a sampling method used to create unique parameter sets
spanning the entire parameter space without testing every possible combination of parameter values. See [3, 15]
for a detailed description and examples of LHS. Both βH
and βM were sampled over uniform distributions by dividing each parameter range into 1,000 equally probable
values. Using LHS, 1,000 unique parameter combinations
were generated spanning the entirety of the (βM , βH ) paDisease-Free Equilibria · The disease-free equilib- rameter space. The model was then simulated for each of
rium of the model without vaccination (α = 0) is given these parameter combinations (using the values given in
Table 1 for all other parameter values). Using the model
by
solution, the number of deaths per day was calculated for
∗
∗
∗
∗
∗
EH
= ER
= IH
= IR
= SV∗ = SRV
=0
each simulation. The weighted error of the daily death
count for each parameter set was calculated using
∗
∗
EM = IM = 0
v
uX 
2
ΩM
u
∗
1
SM =
t
D(t) − Dt ,
(4)
error =
µM
n
t∈T

σ
∗
(2)
SH
= NH 1 +
ρS
where T is the set of times at which a data point exists, n
NH
∗
is the total number of data points, D(t) is the total deaths
SR
=
1 + ρσS
due to yellow fever on day t predicted by the model, and
Dt represents the deaths due to yellow fever on day t as
RV∗ = 0.
given by the data [11]. The set of transmission parameters
Note that without vaccination, the proportion of the pop- giving the lowest error value was used for further model
ulation that remains susceptible to yellow fever (SH ) de- simulations and are given in Table 1.
www.sporajournal.org
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Uncertainty Analysis of Vaccination & Repellent
Parameters · If the values of model parameters are imprecisely known, it is necessary to perform an uncertainty
analysis to predict the variation in model outcomes due to
uncertainty in model parameters. To examine the range
of epidemic outcomes given a range of vaccination and
repellent parameters (see Table 1 for ranges), uncertainty
analysis was utilized. Each of the eight parameters (σ, ρS ,
ρI , ρV , γS , γI , γV , and α) was sampled without replacement over uniform distributions within the ranges given in
Table 1, and LHS was used to generate 1,000 unique parameter combinations which spanned the 8-dimensional
parameter space. The model was simulated for each parameter combination, producing a range of model outcomes as parameters varied.
Sensitivity Analysis of Vaccination & Repellent
Parameters · Model outcomes may be more sensitive
to changes in certain parameters. Sensitivity analyses are
used to determine how sensitive model outcomes are to
changes in uncertain parameters. We modeled 40 different vaccination scenarios (in the absence of the use of insect repellent) using eight different vaccination rates over
five different time periods prior to the introduction of the
first infected human into the population. For each scenario we calculated the cumulative number of infections
and deaths and the peak day of infection.

4

Numerical Results

A Yellow Fever Outbreak without Control Measures · The parameters denoting the transmission rates
of yellow fever, βH and βM were fitted using the data
from the 1878 epidemic in Memphis (see red points in
Figure 1). The transmission rates with the lowest error values (see Equation 4) were βH = 3.92 × 10−7 and
βM = 9.25 × 10−5 . In the fitted model simulation where
no control methods are implemented (see black curve in
Figure 1), the model aligns closely to the data until approximately day 50. At this point, the model overestimates the number of deaths per day until approximately
day 65. The model then underestimates the tail of the
epidemic from days 65 to 100. The combined over approximation and under approximation between days 50
and 100 allows the number of cumulative deaths to be
consistent with the data from the 1878 epidemic, predicting 5,150 total deaths.
Use of vaccination alone · Different vaccination programs can be implemented to decrease the number of susceptible humans in a population over time. Programs
may consider vaccinating during colder months in order
to increase the number of immune individuals in the population before Aedes aegypti activity reaches its peak in
www.sporajournal.org
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warmer months. To model this, vaccination scenarios
were simulated for vaccination occurring in a disease-free
population for 30, 60, 90, 120, and 365 days prior to the
introduction of the first infected human into the population. Additionally, eight different vaccination rates were
simulated for each scenario to account for different vaccination program intensities. Vaccination rates were chosen
such that 10, 20, 30, 40, 50, 60, and 70 percent of the human population would be completely immune (i.e. in the
RV class) after 1 year of vaccination at that rate. The
number of cumulative infections and deaths and the peak
day of infection were calculated for each of these vaccination programs, and are shown in the matrix plots of
Figure 3.
As expected, when the vaccination rate and the period of vaccination prior to the introduction of the first
infectious human increase, the number of cumulative infections and deaths decreases. The cumulative infections
and cumulative deaths matrix plots, shown in Figures
3a and 3b, show that beginning vaccination, even at low
rates, at least a year prior to the epidemic can greatly
decrease the severity of the epidemic by reducing the cumulative number of infections and deaths. Furthermore,
as the vaccination rate and vaccination period increase,
so does the peak day of infection (see Figure 3c). The
higher peak day of infection indicates that the epidemic
is being pushed forward in time, increasing the amount
of time between the onset of the epidemic and its peak.
Thus, an aggressive vaccination campaign over a longer
period of time could result in a small but more prolonged
epidemic.
Use of insect repellent alone · In order to examine
the effects of insect repellent on epidemic severity without the advantages of vaccination, all vaccine parameters
were set to zero. Repellent control parameters were varied within their respective ranges using LHS. Figure 4a
shows the variation in cumulative deaths when only repellent is used as a control measure. The model was simulated 1,000 times with unique parameter sets spanning
the 6-dimensional space of repellent control parameters.
The entire range of output over all 1,000 simulations are
shown by the gray shading between the thick black lines.
The interquartile range (the middle 50% of simulations)
are shown in the red shaded region between the dashed
red lines; the solid red line within the interquartile region
shows the median over all 1,000 simulations. The use of
repellent within the ranges given has little effect on the total number of deaths occurring throughout the epidemic,
as all simulation results appear to approach 5,150 deaths.
However, even modest use of insect repellent does have
a dampening effect on epidemic progression, pushing the
onset of infection forward in time and allowing for a slower
accumulation of deaths over time.
2018 Volume 4(1) page 20
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(a) Cumulative infections

Middleton, Deery, Bodine

(b) Cumulative deaths

(c) Peak day of infection

Figure 3: Cumulative infections (a), cumulative deaths (b), and peak day of infections (c) for 40 different vaccination
scenarios. The darker colors represent increased severity of the epidemic, while the lighter colors represent decreased
epidemic severity.

www.sporajournal.org
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(a) Cumulative deaths; repellent only

(c) Proportion of human population wearing repellent,
(SR + ER + IR + SRV )/NH

Middleton, Deery, Bodine

(b) Cumulative deaths; vaccination & repellent

(d) Proportion of human population immune to yellow fever,
(RH + RV )/NH

(e) Proportion of human population infectious with yellow
fever, A = (IH + IR )/NH

Figure 4: Variation in model outcomes given uncertainty in model repellent parameters only (Figure (a)), and
vaccination and repellent parameters (Figures (b–e)). The upper and lower solid black curves denote maximum and
minimum simulation results, respectively. The red dashed curves represent the first and third quartile, and the red
solid curve represents the median. Cumulative death data from the 1878 epidemic is shown by the black data points
for comparison in Figures (a & b), while the no control simulation is shown by a dark blue curve.

www.sporajournal.org
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Use of vaccination & insect repellent · Uncertainty
in the control parameters for vaccination (α) and use of
insect repellent (σ, ρS , ρI , ρV , γS , γI , and γV ) leads
to variation in model outcomes, as shown in Figure 4.
Each graph in Figure 4 shows the results of 1,000 simulations generated with unique parameter combinations
which span the 8-dimensional parameter space for vaccination and insect repellent parameters. The full range of
output over all 1,000 simulations are shown in the shaded
region between the thick black lines, while the interquartile range are shown in the red shaded region between
the dashed red lines; the solid red line within the interquartile region shows the median over all 1,000 simulations. Variation in model output is shown for cumulative
deaths (Figure 4b); proportion of humans wearing repellent, (SR + ER + IR + SRV )/NH (Figure 4c); proportion
of humans with immunity to yellow fever, (RH +RV )/NH
(Figure 4d), and the proportion of the human population
which is infectious, A = (IH + IR )/NH (Figure 4e).
Figure 4b also shows the cumulative deaths due to yellow fever from the 1878 Memphis epidemic data as a basis
of comparison. Notice that the epidemic is delayed in every simulation in Figure 4b, indicating that even a small
amount of control use can postpone the epidemic. However, the use of vaccination and insect repellent as control
measures at the onset of the epidemic did not completely
eradicate the epidemic in any simulation. Furthermore,
the upper end of the range of cumulative deaths approach
the cumulative death data, i.e. the cumulative deaths accumulated when no vaccination and repellent are used;
these simulations correspond to low vaccination rates in
conjunction with low repellent reapplication rates and a
short period of effectiveness of insect repellent.
Figure 4d shows that when vaccination and insect repellent are used as control measures, the majority of humans who survived the epidemic are immune to yellow
fever by tf = 142 days because they were either vaccinated and ended up in the RV class or because they
became infected with yellow fever and recovered, ending up in the RH class. Furthermore, since the model
assumes that immune individuals do not wear repellent,
Figure 4c shows that very few humans are wearing repellent by tf = 142 days across all simulations, and that the
proportion of humans wearing repellent decreases over the
course of the epidemic as individuals move into one of the
immune classes.
Lastly, Figure 4e shows the proportion of the human
population that is infectious with yellow fever over the
course of the epidemic. As expected, increased levels of
control can decrease the number of infections over time.
However, note that the day of peak infection is shifted
between simulations, occurring early in the epidemic, approximately 70 days after the onset, when modest control
measures are applied (upper black line). When very high
www.sporajournal.org
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control parameters are used (lower black line), the peak
day of infection is pushed back to approximately 95 days
after the onset of the epidemic. The median control use
(red line) shows the peak day of infection being pushed
back to approximately 105 days after the onset.

5

Conclusions

We used historical epidemic records to parameterize a
novel yellow fever model and then examined the impact
of vaccination and insect repellent on the dynamics and
outcomes of a yellow fever outbreak. Our results show
that the preventative measure of vaccination is most effective when implemented prior to the onset of the epidemic.
The longer a vaccination campaign is in place before the
start of an outbreak, the more likely it is to quell the epidemic completely. Our results also showed that the use
of disease prevention programs may delay the progression of the epidemic, while not preventing it all together.
This is especially important in climates with seasonality
where mosquito activity decreases in colder seasons. In
these regions, delaying the epidemic offers another level
of control.
Since vaccines are not readily available or easily accessible in all areas affected by yellow fever, the use of repellent
to avoid human-to-mosquito contact can further prevent
the spread of an epidemic. The habitual application of
insect repellent is important after the onset of the epidemic due to the waning effectiveness of repellent. Our
results show that the use of insect repellent along with
vaccination starting at the beginning of an outbreak can
be effective in significantly reducing the number of cumulative infections and deaths over the course of the epidemic. However, this control strategy is unable to completely prevent the epidemic. Repellent alone can also be
used to slow the progression of an epidemic but is not
effective to prevent the spread of infection when it is the
sole control measure used.
The use of historical medical records to model yellow
fever can provide great insight as to how we control yellow fever epidemics today. While medicine has seen significant advancements since 1878, there are still many
parts of the world affected by yellow fever with limited
access to medical care. The model results of vaccination and insect repellent as control measures can be applied to yellow fever epidemics in these areas today. This
model could also be adapted for other vector-borne diseases such as Dengue, West Nile, Malaria, and Zika by
redefining disease-specific parameters and refitting transmission parameters. The model could then be used to
estimate the vaccine efficacy, vaccination rate, and repellent application strategies needed to prevent outbreaks of
these diseases.
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